CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
N-acetylcysteine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02499029
NCT02499029Phase 2Completed
CompareCT.gov

Glial Regulators for Treating Comorbid Posttraumatic Stress and Substance Abuse Disorders

Medical University of South Carolina·interventional·Posted Jul 15, 2015·Updated Aug 29, 2018

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine and Placebo for PTSD and Addiction. Completed, enrolled 35 participants.

Detailed Summary

Examine the effects of N-acetylcysteine on PTSD symptoms, craving and substance use in veterans with PTSD and comorbid substance use disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD, Addiction
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2015
Enrollment StartFeb 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.0 years ago

Interventions

N-acetylcysteinedrug

NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.

Placebodrug

Identical looking placebo pills were administered each week.